CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7,857 enrolled
Drug / intervention
Tiotropium Respimat® +1 moredrug
Likely dose
Tiotropium Respimat® 1.25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03964220
NCT03964220N/ACompleted
CompareCT.gov

The Effectiveness of Tiotropium Add-on Therapy Using a Real-world Cohort of Patients With Asthma

Boehringer Ingelheim·observational·Posted May 28, 2019·Updated Nov 3, 2020

In Brief

An observational study evaluating Tiotropium Respimat® and Inhaled Corticosteroid/Long-acting beta-agonist for Asthma. Completed, enrolled 7,857 participants across 1 site.

Detailed Summary

To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 28, 2019
Enrollment StartMar 15, 2019
Primary CompletionSep 20, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.1 years ago

Interventions

Tiotropium Respimat®drug

Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )

Inhaled Corticosteroid/Long-acting beta-agonistdrug

baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA